首页> 外文期刊>Nature reviews neuroscience >Assessment and management of coronary artery disease in kidney and pancreas transplant candidates
【24h】

Assessment and management of coronary artery disease in kidney and pancreas transplant candidates

机译:肾脏和胰腺移植候选冠状动脉疾病的评估与管理

获取原文
获取原文并翻译 | 示例
           

摘要

Patients with end-stage renal disease (ESRD) undergoing evaluation for kidney and/or pancreas transplantation represent a population with unique cardiovascular (CV) profiles and unique therapeutic needs. Coronary artery disease (CAD) is common in patients with ESRD, mediated by both the overrepresentation and higher prognostic value of traditional CV risk factors amongst this population, as well as altered cardiovascular responses to failing renal function, likely mediated by dysregulation of the renin-angiotensin-aldosterone system (RAAS) and abnormal calcium and phosphate metabolism. Within the ESRD population, obstructive CAD correlates highly with adverse coronary events, including during the peri-transplant period, and successful revascularization may attenuate some of that increased risk. Accordingly, peri-transplant coronary risk assessment is critical to ensuring optimal outcomes for these patients. The following provides a review of CAD in patients being evaluated for kidney and/or pancreas transplantation, as well as evidence-based recommendations for appropriate peri-transplant evaluation and management.
机译:接受肾脏和/或胰腺移植评估的终末期肾病(ESRD)代表了具有独特心血管(CV)型材和独特治疗需求的人群。冠状动脉疾病(CAD)在ESRD患者中是常见的,通过这种人群中的过度陈述和传统CV风险因素的高度陈述和更高的预后价值,以及改变的心血管反应失败的肾功能,可能是由肾素的失调介导的血管紧张素 - 醛固酮系统(RAA)和异常钙和磷酸盐代谢。在ESRD人群中,阻塞性CAD与不良冠状动脉事件高度相关,包括在PERI移植期间,并且成功的血运重建可能会衰减其中一些风险。因此,Peri移植冠状动脉风险评估对于确保这些患者的最佳结果至关重要。以下为评估肾脏和/或胰腺移植评估的患者的CAD提供了审查,以及针对适当的PERI移植评估和管理的证据建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号